If you want to distinguish your goods, services or both from those of another company, you may need a trademark or trade name. Find out what they are, what their registration procedure is and what it involves.
Information on the deadlines for filing applications for transformation of European Union trademarks into Spanish national trademarks. See more
If you have a new device, product or procedure that solves a technical problem or has a practical advantage, there are different ways to protect it in Spain and other countries. Find out how.
Does your innovation lie in the aesthetics, ornamentation or appearance of your product? Protect it through industrial design. Find out what rights registration confers and how to proceed.
Geographical indications protect the name of a product that has a specific geographical origin and owes its qualities, characteristics or reputation to its particular origin. Find out what they are, how the registration process works and what benefits they provide.
Patents published worldwide are a valuable source of scientific, technical and commercial information.
El Bono 3 del Fondo para PYMEs 2025, que cubre la elaboración de Informes Tecnológicos de Patentes (ITP) y Búsquedas Retrospectivas se cerrará el lunes 10 de febrero de 2025 al cierre de la jornada laboral. Próximamente se informará sobre su reapertura. Puede consultar más información aquí.
If you are an entrepreneur or a company and you want to boost and improve the profitability of your business by adequately protecting the intangible assets of your organisation, in this space you will find what you need.
185
results.
Updated on
24/02/2026 [06:50:00]
Absstract of: US20260048012A1
The present invention concerns a method for the production, purification, and stabilization of plant-derived nanovesicles (PDVs). It also concerns a pharmaceutical composition comprising the PDVs obtained by this method for hypocholesterolemic, hypoglycemic, hypolipidemic, anti-ageing, and antioxidant use.
Absstract of: WO2026038042A1
The present invention is directed to peptide modified polymers, nanoparticle compositions comprising peptide modified polymers, nanoparticle compositions comprising a polynucleotide in addition to peptide modified polymers, methods for preparing said peptide modified polymers and nanoparticle compositions, and uses thereof. The polymers can in particular be poly(beta-aminoesters).
Absstract of: US20260049162A1
Chitosan nanoparticles include chitosan and more than one lasso peptide, wherein the lasso peptide has a carboxyl group; an amino group in the structure of the chitosan is connected to the carboxyl group of the lasso peptide via an amide bond.
Absstract of: US20260049154A1
An immuno-nanolipoprotein particle (Immuno-NLP) comprising one or more membrane forming lipids, a scaffold protein and an immune cell transmembrane protein, and methods of using immuno-nanolipoprotein particles to deliver immune cell transmembrane protein to immune cells, and related compositions, methods, and systems.
Absstract of: US20260048152A1
The present invention relates to an inorganic-organic hybrid compound as ionic compound, composed of an inorganic metal cation selected from ZrO2+, and of an organic active ingredient anion selected from gemcitabine monophosphate or gemcitabine triphosphate.
Absstract of: US20260048142A1
The disclosure relates to the technical field of biological medicines, and particularly provides a metal-chelated polyphenol complex nanoparticle, a drug-lipid particle, preparation methods for the same, and the uses thereof. The present disclosure provides a metal-chelated polyphenol complex as a carrier for drugs for stability, delivery and the like, so that it interacts with other carriers to form a metal-chelated polyphenol complex nanoparticle for effective administration of negatively charged drug. High-efficiency systemic drug delivery can be achieved, while toxicity is significantly reduced compared to LNP containing cationic or ionizable lipids, enabling safe and effective treatment of diseases or disorders.
Absstract of: US20260048141A1
This disclosure relates to polyethylene glycol (PEG)-functionalized nanoparticles comprising a functional agent, and preparation methods, properties and applications thereof. The nanoparticle represented by PEG-L-G/P, comprising a type of hydrophilic PEG, a hydrophobic functional agent G, which are covalently linked by L: a linker or a chemical bond, and a type of hydrophobic polymer P. The G and P form the hydrophobic core, while the PEG constitutes the hydrophilic outer layer of the nanoparticle in an aqueous medium. The functional agent comprises one or more functional compounds including a therapeutic drug, an imaging diagnostic agent, a photoelectric responsive diagnostic agent, an immune-stimulating agent, or a combination thereof. The nanoparticles comprising such functional agent can offer various applications in multiple biomedical fields.
Absstract of: US20260048128A1
The subject invention pertains to a novel composition comprising a self-therapeutic metal nanoparticle core coated with a hydrophilic polymer, and optionally a therapeutic agent linked to the polymer. The linker comprises functional groups that can bind to both the metal core and the polymer. The subject invention further discloses a method for treating HD in a subject comprising administering an effective amount of the composition to a subject with HD. The composition exhibits self-therapeutic properties when administered to patients with Huntington's disease. Additionally, the invention comprises a method for synthesizing gold nanoparticles for treating Huntington's disease. This method comprises conjugating gold nanoparticles with polyethylene glycol (PEG) and attaching a therapeutic agent via a linker to the PEG. This enables targeted delivery of the therapeutic agent to its therapeutic targets.
Absstract of: US20260048127A1
The present invention, based on a non-bubble-based sonoporation technique, provides an ultrasound-assisted delivery platform for drug-loaded chitosan nanoparticles. This platform comprises: the administration of drug-loaded chitosan nanoparticles and the application of ultrasound stimulation. The drug-loaded chitosan nanoparticles are delivered to a target site, where ultrasound waves are directly applied to induce cellular membrane deformation. The ultrasound mechanical force temporarily alters membrane permeability, thereby facilitating the intracellular delivery of the drug-loaded chitosan nanoparticles.
Absstract of: US20260048118A1
Compositions for improved gene editing and methods of use thereof are disclosed. In a preferred method, gene editing involves use of a cell-penetrating anti-DNA antibody, such as 3E10, as a potentiating agent to enhance gene editing by nucleases and triplex forming oligonucleotides. Genomic modification occurs at a higher frequency when cells are contacted with the potentiating agent and nuclease or triplex forming oligonucleotide, as compared to the absence of the potentiating agent. The methods are suitable for both ex vivo and in vivo approaches to gene editing and are useful for treating a subject with a genetic disease or disorder. Nanoparticle compositions for intracellular delivery of the gene editing compositions are provided and are particularly advantageous for use with in vivo applications.
Absstract of: US20260048022A1
A novel targeting process and nanoparticle design is disclosed, improving delivery of drugs and other pay load materials to tumors and other sites of interest. In a preferred embodiment, endothelial cells are damaged at the target site, thereby activating platelets. Nanoparticles bearing fibrinogen or other materials that bind to activated platelets are administered that also contain one or more drugs or other pay load substances thereby improving payload delivery to the targeted site.
Absstract of: US20260048014A1
The present invention is related to the field of targeted drug delivery. In particular, the particles and compositions described herein are used to deliver drugs to treat the diseases and conditions of interest. These particles and compositions include, but are not limited to, the lipopeptide complexes that mimic human high-density lipoproteins but contain apolipoprotein fragments or combination thereof.
Absstract of: US20260048140A1
A copolymer in which a target-affinity molecule is bonded to a copolymer X having structural units of (A), (B), and (C):R1, R2, and R3 are the same or different and are hydrogen or C1-3 alkyl. R4 is C1-3 alkyl. R5 is hydrogen, C1-18 alkyl, 3- to 8-membered cycloalkyl optionally having a substituent, adamantyl, C6-18 aryl optionally having a substituent, or a 5- to 10-membered heteroaryl optionally having a substituent. X1, X2, and X3 are the same or different and are oxygen, sulfur, or N—R7. R6 is hydrogen, a leaving group, or a linker. R7 is hydrogen or C1-3 alkyl. m is a number of 1 to 100, and n is 0 to 3.
Absstract of: US20260048108A1
The disclosure provides compositions, methods of treatment, and methods of making and using compositions to deliver a nucleic acid to a subject. Compositions described herein include lipid carriers, optionally including an inorganic particle, capable of admixing with nucleic acids. Nucleic acids provided herein include those encoding for cancer antigens (full length proteins or fragments) as well as antibodies. Methods of using the compositions as a therapeutic vaccine for the treatment of a cancer are also provided.
Absstract of: US20260048105A1
Breast cancer is now the most prevalent cancer worldwide, and despite therapeutical advances in the last decades, metastatic breast cancer remains an incurable disease. Novel tumor-specific antigens (TSAs) and tumor-associated antigens (TAAs) expressed by breast tumor cells are described herein. Synthetic long peptides, nucleic acids, compositions, cells, TCRs, antibodies and vaccines derived from these TSAs and TAAs are described. The use of the TSAs/TAAs, nucleic acids, compositions, antibodies, cells and vaccines for the prevention or treatment of breast cancer, including triple-negative breast cancer (TNBC), is also described.
Absstract of: US20260048023A1
The present disclosure relates to lipid nanoparticles for delivery of DNA, the lipid nanoparticle comprising therein a DNA-binding protein or peptide bound to the DNA, and uses thereof.
Absstract of: US20260048024A1
Lipid nanoparticles (LNPs) are widely used for RNA delivery but are limited by inefficient RNA release following endosomal escape. Disclosed herein are hybrid polymer-lipid nanoparticles (PLNPs) incorporating acid-responsive poly(lactic acid)-block-poly(carboxybetaine) zwitterionic polymers to enhance RNA delivery efficiency. The polymers are cationic at physiological pH to enable RNA complexation but become neutral at endosomal pH, reducing RNA binding affinity and promoting release. These polymers were integrated into clinically approved LNP formulations to form PLNPs. The resulting PLNPs showed up to a 5.4-fold decrease in siRNA IC50 values and a 4-fold increase in mRNA transfection across multiple cell lines. Enhanced cytosolic RNA levels were confirmed via confocal microscopy, with uptake and endosomal escape comparable to standard LNPs. The improvement in transfection efficiency was lost when acid-inert polymers were used, confirming the role of the acid-responsive polymers. This approach provides a versatile platform to improve RNA delivery from existing LNP systems.
Absstract of: US20260048010A1
Articles, compositions, kits, and methods relating to nanostructures, including synthetic nanostructures, are provided. Certain embodiments described herein include structures having a core-shell type arrangement; for instance, a nanostructure core may be surrounded by a shell including a material, such as a lipid bilayer, and may include other components such as oligonucleotides. In some embodiments, the structures, when introduced into a subject, can be used to deliver nucleic acids and/or can regulate gene expression. Accordingly, the structures described herein may be used to diagnose, prevent, treat or manage certain diseases or bodily conditions. In some cases, the structures are both a therapeutic agent and a diagnostic agent.
Absstract of: US20260048013A1
The present invention relates to a pharmaceutical formulation comprising at least one active pharmaceutical ingredient (API) having low aqueous solubility or a pharmaceutically acceptable salt thereof in the form of particles of a size between 1 and 800 nm, wherein said particles are encapsulated within a large microparticle of a size between 1 and 100 μm formed by a matrix comprising at least an excipient. Therefore, the API is entrapped or encapsulated in the microparticles of excipients. This pharmaceutical formulation contains the pharmaceutical active ingredient having improved solubility and subsequently supra-bioavailability.
Absstract of: US20260048021A1
The present invention provides: a neutral lipid capable of suppressing the phase transition of endosomal membranes caused by phosphatidylcholine from being inhibited; and a lipid nanoparticle containing the neutral lipid. The present invention pertains to an ionic neutral lipid comprising a compound represented by general formula (I). In formula (I), R1 is a C1-22 hydrocarbon group; three R1 groups in one molecule may be the same as or different from each other; a1 and a2 are each independently an integer of 0 to 4; b1 and b2 are 0 or 1, satisfying b1+b2=1; R2 and R3 are each independently a hydrogen atom or a C1-3 alkyl group; and R4 is an anionic group.
Absstract of: AU2024321749A1
A method of generating a plurality of different surface-decorated nanoparticles, decorated with different surface decoration, comprising: forming a plurality of microdroplets in a microfluidics device, each microdroplet comprising a nanoparticle and a respectively different macromolecule encoding a different surface decoration molecule; synthesising the surface decoration molecule, within each microdroplet, based on the macromolecule encoding the surface decoration molecule; conjugating the nanoparticle and the surface decoration molecule, within each microdroplet, to form surface decorated nanoparticles.
Absstract of: AU2024293559A1
Provided is a diester lipid compound of Formula (I) or a pharmaceutically acceptable salt thereof The compound can be used to obtain lipid nanoparticles. In some embodiments, the lipid nanoparticle can comprise (a) from about 40 to about 100 mol % of the compound of Formula (I); (b) from 0 to about 10 mol % of a neutral lipid; (c) from 0 to about 50 mol % of a helper lipid; (d) from 0 to about 5 mol % of a polymer-conjugated lipid; and (e) from 0 to about 5 mol % of a hydrophobic component; wherein the mol % are based on the total lipids present in the nanoparticle. (I)
Absstract of: US20260048005A1
Disclosed herein are injectable hydrogel formulations prepared by integrating crosslinked hyaluronic acid into Pluronic F127 for an extended release of DFO nanochelators. Methods of manufacture and of use are also provided.
Absstract of: US2024269085A1
The present invention provides stable, non-degradable edible, inhalable, soluble and drinkable compositions comprising highly bioavailable pharmaceutical grade ultrafine active pharmaceutical ingredients having 99% purity and 200% increased bioavailability and methods for their production.
Nº publicación: WO2026037391A1 19/02/2026
Applicant:
SHANGHAI VITALGEN BIOPHARMA CO LTD [CN]
SHANGHAI VITALGEN BIOPHARMA CO., LTD
Absstract of: WO2026037391A1
A lipid nanoparticle composition targeting to antigen-presenting cells (APCs), comprising: at least a therapeutic agent, at least a cationic or ionizable cationic lipid, at least a neutral lipid, at least a steroid or steroid analogue, at least a PEGylated lipid, and atleast a phosphatidylglycerol.
BOPI
Electronic site
